RxDoctor Payments Data
★ My doctorsLook up a doctor →

Omid Rabbani, MD

Neurology · Simi Valley, CANPI 1033296587

Payments from drug & device makers

$50,582in general payments, 2019–2025

Across 776 payments — averaging $65.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$39K
  • AbbVie$2K
  • UCB, Inc.$700
  • Amgen$551
  • Novartis$551
  • Teva Pharmaceuticals USA, Inc.$550
  • plus $8K from 52 others

What the payments were for

  • Speaking & faculty fees$1021%
  • Food & beverage$11,98698%
  • Education$1361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.25$38,504
AbbVie(2 entities)162$1,885
UCB, Inc.29$700
Amgen(2 entities)28$551
Novartis38$551
Teva Pharmaceuticals USA, Inc.26$550
SK Life Science, Inc.34$444
MDD US Operations, LLC33$437
Amneal Pharmaceuticals LLC29$423
AstraZeneca(2 entities)17$418
Biogen26$417
CSL Behring20$390
EMD Serono, Inc.19$358
Acorda Therapeutics, Inc16$319
Sunovion Pharmaceuticals Inc.14$288
Biohaven Pharmaceuticals, Inc.32$275
Biohaven Pharmaceutical Holding Company Ltd.32$266
Pfizer23$256
Genentech USA, Inc.12$252
Lilly USA, LLC13$249
Takeda Pharmaceuticals U.S.A., Inc.10$217
Sanofi10$209
Greenwich Biosciences, Inc.9$201
Lundbeck LLC9$200
Acadia Pharmaceuticals Inc11$198
Kyowa Kirin, Inc.9$182
Supernus Pharmaceuticals, Inc.8$129
Neurocrine Biosciences, Inc.5$120
Argenx US, Inc.5$105
Nevro Corp.3$95
Neurelis, Inc.5$91
Upsher-smith Laboratories LLC4$90
Livanova USA, Inc.5$88
Alnylam Pharmaceuticals Inc.4$82
Aquestive Therapeutics, Inc.5$80
Akcea Therapeutics, Inc.3$79
Otsuka America Pharmaceutical, Inc.3$76
TG Therapeutics, Inc.3$74
Idorsia Pharmaceuticals US Inc3$66
Abbott3$64
Banner Life Sciences, LLC3$61
Impel Pharmaceuticals Inc.3$57
Tanabe Pharma America, Inc.3$51
Jazz Pharmaceuticals Inc.2$49
Mallinckrodt Hospital Products Inc.2$47
Adamas Pharmaceuticals, Inc.2$45
Avanir Pharmaceuticals, Inc.2$39
Merz North America, Inc.2$32
Merz Pharmaceuticals, LLC2$31
Assertio Therapeutics, Inc.2$31
Sumitomo Pharma America, Inc.1$27
Promius Pharma LLC1$25
Bristol Myers Squibb1$21
Grifols USA, LLC1$20
Catalyst Pharmaceuticals, Inc.1$19
Boston Scientific1$18
Xeris Pharmaceuticals, Inc.1$17
Vertical Pharmaceuticals, LLC1$15

How this compares

$50,582 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024
$17,004
Medicare patients
98
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl21$1,303
Donepezil Hcl26$738

Paid to pharmacies, not to this prescriber.

Other neurology in Simi Valley

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →